

## Supplemental Material Table of Contents

1. Supplemental Table 1. RNA sequencing identification of proximal tubule marker expression in HPTC
2. Supplemental Table 2. qPCR primers list
3. Supplemental Figure 1: EGFR ligand dose response in HPTC.
4. Supplemental Figure 2. sAREG and sHB-EGF differentially regulate EGFR cell-surface levels in HPTCs.

### Supplemental Table 1. RNA sequencing identification of proximal tubule marker expression in HPTC

Ensembl gene ID	Gene name	CPM	Expression Ranking
ENSG00000245532	NEAT1	426.052957	298
ENSG00000054654	SYNE2	140.832669	1355
ENSG00000099250	NRP1	112.058187	1796
ENSG00000090565	RAB11FIP3	66.0499293	>2000
ENSG00000022556	NLRP2	43.4322078	>2000
ENSG00000111961	SASH1	34.4933133	>2000
ENSG00000048471	SNX29	17.774747	>2000
ENSG00000069020	MAST4	14.1940371	>2000
ENSG00000066230	SLC9A3	13.3954615	>2000
ENSG00000173068	BNC2	12.5711254	>2000
ENSG00000169760	NLGN1	2.29268475	>2000
ENSG00000262619	LINC00621	0.9016176	>2000
ENSG00000158296	SLC13A3	0.85009659	>2000
ENSG00000100031	GGT1	0.85009659	>2000
ENSG00000153707	PTPRD	0.20608402	>2000
ENSG00000107611	CUBN	0.20608402	>2000
ENSG00000166415	WDR72	0.05152101	>2000
ENSG00000228262	LINC01320	0.0257605	>2000

CPM: Counts per million



Supplemental Table 2. qPCR primers list

Target gene	Synonym	Species	Direction	Sequence
<b>ADAM17</b>	TACE	human	Forward	AGTGCAGTGACAGGAACAGT
<b>ADAM17</b>	TACE	human	Reverse	GGACACGCCTTTGCAAGTAG
<b>AREG</b>		human	Forward	TCGGCTCAGGCCATTATGC
<b>AREG</b>		human	Reverse	AATCCATCAGCACTGTGGTCC
<b>EGF</b>		human	Forward	CTTGGGAGCCTGAGCAGAAA
<b>EGF</b>		human	Reverse	TGCACAAGTGTGACTGGAGC
<b>EGFR</b>		human	Forward	CGAATGGGCCTAAGATCCCG
<b>EGFR</b>		human	Reverse	CTTCGCATGAAGAGGCCGAT
<b>EPGN</b>		human	Forward	ACAGAAGCTGACAACATAGA
<b>EPGN</b>		human	Reverse	AGCTCATGGTGGGAATGCACA
<b>EREG</b>		human	Forward	ACGTGTGGCTCAAGTGTCAA
<b>EREG</b>		human	Reverse	CACTTCACACCTGCAGTAGTT
<b>GAPDH</b>		human/mouse	Forward	ACCACAGTCCATGCCATCAC
<b>GAPDH</b>		human/mouse	Reverse	TCCACCACCCTGTTGCTGTA
<b>HBEGF</b>		human	Forward	TTGTGCTCAAGGAATCGGCT
<b>HBEGF</b>		human	Reverse	CAACTGGGGACGAAGGAGT
<b>PRLP0</b>		human	Forward	CGTCTCGTGGAAGTGACAT
<b>PRLP0</b>		human	Reverse	TAGTTGGACTTCCAGGTCGC
<b>TGFA</b>		human	Forward	GTA AAAATGGTCCCCTCGGCT
<b>TGFA</b>		human	Reverse	GGGTCTGCACTCAGCGG
<b>YAP1</b>	YAP	human	Forward	TGATGGATGGGAACAAGCCA
<b>YAP1</b>	YAP	human	Reverse	TGGTTCATGGCAAACGAGG
<b>Acta2</b>	$\alpha$ SMA	mouse	Forward	AGCCATCTTTTATTGGGATGC
<b>Acta2</b>	$\alpha$ SMA	mouse	Reverse	TACCCCTGACAGGACGTTG
<b>Adam17</b>	Tace	mouse	Forward	TCTGAAGAGTTTGTTCGTGCA
<b>Adam17</b>	Tace	mouse	Reverse	CTTCTCCACGGCCCATGTAT
<b>Areg</b>		mouse	Forward	GCTGAGGACAATGCAGGGT/
<b>Areg</b>		mouse	Reverse	GTGACA ACTGGGCATCTGGA
<b>Ccl2</b>	Mcp1	mouse	Forward	CACTCACCTGCTGCTACTCA
<b>Ccl2</b>	Mcp1	mouse	Reverse	GCTTGGTGACAAAACTACA/
<b>Ccl3</b>	Mip1A	mouse	Forward	CAGCCAGGTGTCATTTTCTG
<b>Ccl3</b>	Mip1A	mouse	Reverse	TCTCAGGCATTAGTTCCAGG
<b>Ccl5</b>	Rantes	mouse	Forward	CTCACCATATGGCTCGGACA
<b>Ccl5</b>	Rantes	mouse	Reverse	CGACTGCAAGATTGGAGCAC
<b>Egf</b>		mouse	Forward	AGCATACTCAGCGTCACAGC
<b>Egf</b>		mouse	Reverse	GCAGGACCGGCACAAGTC
<b>Egfr</b>		mouse	Forward	ACCTCTCCCGTTCAGAGATG
<b>Egfr</b>		mouse	Reverse	CTTGTGCCTTGGCAGACTTTC
<b>Epgn</b>		mouse	Forward	AACAACACCGAAGCTGACTAC



Supplemental Table 2 (cont.)

<b>Epgn</b>		<b>mouse</b>	<b>Reverse</b>	<b>TGGTGGGAATGCACATGCTCC</b>
<b>Ereg</b>		mouse	Forward	TGCTTTGTCTAGGTTCCCACC
<b>Ereg</b>		mouse	Reverse	GGCGGTACAGTTATCCTCGG
<b>Hbegf</b>		mouse	Forward	TCTGGCCGCAGTGTTGTCC
<b>Hbegf</b>		mouse	Reverse	GGTTTGTGGATCCAGTGGGA
<b>Prpl0</b>		mouse	Forward	CTCTCGCTTTCTGGAGGGTG
<b>Prpl0</b>		mouse	Reverse	ACGCGCTTGTACCCATTGAT
<b>Tgfa</b>		mouse	Forward	CTCTGCTAGCGCTGGGTATC
<b>Tgfa</b>		mouse	Reverse	TGGGCACTTGTTGAAGTGAG
<b>Tgfb1</b>	Tgfβ	mouse	Forward	CTGCTGACCCCCACTGATAC
<b>Tgfb1</b>	Tgfβ	mouse	Reverse	AGCCCTGTATTCCGTCTCCT
<b>Tnf</b>	Tnfa	mouse	Forward	ATGGCCTCCCTCTCATCAGT
<b>Tnf</b>	Tnfa	mouse	Reverse	CTTGGTGGTTTGCTACGACG
<b>Yap1</b>	Yap	mouse	Forward	TTCGGCAGGCAATACGGAAT
<b>Yap1</b>	Yap	mouse	Reverse	CATCCTGCTCCAGTGTAGGC

Suppl. Fig. 1: Dose-response curves and maximal EGFR phosphorylation by its different ligands in HPTC.






	sHBEGF	sBTC	sEGF	sTGF $\alpha$	sAREG	sEREG	sEPGN
EC50 (nM)	0.18	0.23	0.32	5.23	24.81	28.6	~84



**Supplemental Figure 1: EGFR ligand dose response in HPTC. (A-B)** Serum starved HPTCs were treated for 15 min with increasing amounts of EGFR ligands and EGFR phosphorylation was tested by WB (A). A concentration range of 85 fM – 8.5 pM was used for high affinity and of 1.7 pM – 17 nM for low affinity ligands (stars denote concentration of 8.5 pM in all panels). Dose-response curves (B, right graph) and EC50 values (B, table) were calculated after normalization to 100% of maximal phosphorylation obtained by each ligand. **(C)** HPTCs were treated for 15 min with EGFR ligands in amounts sufficient to induce maximal EGFR phosphorylation by each ligand. EGFR phosphorylation was examined by WB (C, left panel) and densitometric analysis (C, column graph) was performed after normalization to non-stimulated cells. Tubulin was used in all experiments for normalization (loading control).

Suppl. Fig. 2: High affinity ligands also induce AREG release but they lead to internalization of EGFR.





**Supplemental Figure 2. sAREG and sHB-EGF differentially regulate EGFR cell-surface levels in HPTCs. (A)** HPTCs were treated with different EGFR ligands (shown in the legend) for 24h and mRNA expression of endogenous EGFR ligands (shown in x-axis) was tested by qPCR. Results are presented after normalization to control-stimulated cells (fold control). **(B)** Endogenous sAREG released in HPTC culture medium was measured by ELISA after stimulation with soluble high affinity EGFR ligands. Results are presented as percentile of sAREG concentration in medium of control-stimulated cells (% Control). **(C)** HPTCs were treated with equimolar amounts of sAREG or sHB-EGF and surface levels of EGFR were measured by flow cytometry at different time points as noted. Results are presented after normalization to surface EGFR of control-stimulated cells corresponding to each respective time point (% Control). **(D)** HPTCs were treated with equimolar amounts of sAREG or sHB-EGF and EGFR cellular distribution was examined by immunocytochemistry at different time points as noted. **(E)** HPTCs were treated with equimolar amounts of sAREG or sHB-EGF and total EGFR levels were examined by western blot (left panels) and quantified by densitometric analysis (right panel) at different time points as noted. Tubulin was used as loading control. **(F, G)** HPTCs were treated with equimolar amounts of EGFR ligands and total EGFR levels were examined by western blot (top panels) and quantified by densitometric analysis (bottom panels) at different time points as noted. Tubulin was used as loading control. n=3-4 for all experiments, \*: P<0.05, \*\*: P<0.01.